Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Alzheimer’s: New Approaches and New Hope

Unfortunately, 2018 marked yet another bad year for Alzheimer’s disease drug development, with at least half-a-dozen major clinical drug trial failures.

Read More »

Novartis’ SMA Gene Therapy On Fast Track For Approval

Novartis’ gene therapy treatment for spinal muscular atrophy could receive marketing approval as early as May 2019 after the U.S. Food and Drug Administration granted AVXS-101, now dubbed Zolgensma, priority review.

Read More »

Coeptis Pharma Buys Elto Pharma for Phase II Parkinson’s Asset

Wexford, Pa.-based Coeptis Pharmaceuticals is buying New York-based Elto Pharma, which is a joint venture between Amarantus Bioscience Holdings and PsychoGenics.

Read More »

Sanofi and Denali Reach Potential $1+ Billion Deal

Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.

Read More »

Bayer, Orion drug delays spread of prostate cancer

German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.

Read More »

Startup CuraSen Takes Aim at Parkinson’s and Alzheimer’s

San Mateo, Calif.-based startup CuraSen Therapeutics surged forward with $54.5 million in Series A funding and a leadership team that includes executives from Afferent Pharmaceuticals, a company acquired by Merck in 2016 for $1.2 billion.

Read More »

Can AI Detect Parkinson’s Disease from a Video? Tencent and Medopad Team up to Find Out

Medopad, a U.K.-based medical firm, and China-based Tencent Holdings have teamed up on a project that will attempt to harness artificial intelligence in the diagnosis of Parkinson’s disease.

Read More »

Impatient patients turn to online ‘buyers club’ for new drugs

Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club.

Read More »

Elevian Launches to Join Numerous Companies Focused on Longevity and Aging

In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding.

Read More »

Teva Returns Laquinimod Rights to Active Biotech

Active Biotech regained the global development and commercialization rights to the neurodegenerative disease drug laquinimod from Teva Pharmaceutical Industries.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!

Subscribe

Ad Right Bottom